MiMedx Group (NASDAQ:MDXG) Announces Earnings Results

MiMedx Group (NASDAQ:MDXG) posted its quarterly earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, FiscalAI reports. MiMedx Group had a positive return on equity of 2.32% and a negative net margin of 6.32%. The business had revenue of $62.28 million during the quarter, compared to analysts’ expectations of $68.56 million.

Here are the key takeaways from MiMedx Group’s conference call:

• Surgical revenue grew 9% year over year, with volume increasing in the mid-teens and broad-based growth across placental sheets, particulates, and newer products. Management expects high-single-digit surgical growth in the fourth quarter.
• Total third-quarter sales fell 45% to $62 million, driven by a 71% decline in wound-care revenue following Medicare reimbursement changes. Although wound-care-center volume rose 7% sequentially, management said the market remains difficult to forecast and expects 2027 conditions to resemble 2026.
• Cost reductions and manufacturing improvements helped gross margin improve to 80% and returned the company to positive Adjusted EBITDA of $2 million, a roughly $10 million sequential improvement. Management expects further sequential EBITDA improvement in the fourth quarter and ended the period with $121 million in net cash and no debt.
• MiMedx reached a $25 million patent settlement and licensing agreement, while a federal court vacated the FDA’s adverse classification of AXIOFILL and remanded the matter for further consideration. Two additional patent cases remain active, with management citing favorable claim-construction rulings.
• The FTC issued a second request for information regarding the Sanara MedTech acquisition, delaying the closing timeline and triggering a ticking fee on MiMedx’s proposed $300 million acquisition financing. Management remains committed to the transaction, which it expects would add more than $100 million of revenue, at least $20 million in annual synergies, and an Adjusted EBITDA margin above 20%, but no closing date was provided.

MiMedx Group Price Performance

Shares of MDXG traded down $0.09 on Friday, reaching $3.88. The stock had a trading volume of 433,124 shares, compared to its average volume of 1,305,756. MiMedx Group has a twelve month low of $3.03 and a twelve month high of $7.97. The firm has a market capitalization of $566.28 million, a PE ratio of -29.81 and a beta of 1.18. The firm has a 50-day moving average of $4.49 and a 200 day moving average of $4.30. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on MDXG shares. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday. Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a research report on Monday, August 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of MiMedx Group in a research note on Tuesday, September 15th. Seaport Research Partners lowered shares of MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Finally, Wall Street Zen raised MiMedx Group from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.14.

About MiMedx Group

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.